IL-3 Decreases Cartilage Degeneration by Downregulating Matrix Metalloproteinases and Reduces Joint Destruction in Osteoarthritic Mice

J Immunol. 2016 Jun 15;196(12):5024-35. doi: 10.4049/jimmunol.1500907. Epub 2016 May 13.

Abstract

Osteoarthritis (OA) is a chronic disease of articular joints that leads to degeneration of both cartilage and subchondral bone. These degenerative changes are further aggravated by proinflammatory cytokines including IL-1β and TNF-α. Previously, we have reported that IL-3, a cytokine secreted by activated T cells, protects cartilage and bone damage in murine models of inflammatory and rheumatoid arthritis. However, how IL-3 protects cartilage degeneration is not yet known. In this study, we investigated the role of IL-3 on cartilage degeneration under both in vitro and in vivo conditions. We found that both mouse and human chondrocytes show strong expression of IL-3R at gene and protein levels. IL-3 increases the expression of mouse chondrocyte-specific genes, Sox9 and collagen type IIa, which were downregulated by IL-1β. Moreover, IL-3 downregulated IL-1β- and TNF-α-induced expression of matrix metalloproteinases in both mouse and human chondrocytes. Interestingly, IL-3 reduces the degeneration of articular cartilage and subchondral bone microarchitecture in a mouse model of human OA. Moreover, IL-3 showed the preventive and therapeutic effects on cartilage degeneration induced by IL-1β in micromass pellet cultures of human mesenchymal stem cells. Thus, to our knowledge, we provide the first evidence that IL-3 has therapeutic potential in amelioration of degeneration of articular cartilage and subchondral bone microarchitecture associated with OA.

MeSH terms

  • Animals
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / immunology
  • Cartilage, Articular / pathology*
  • Cells, Cultured
  • Chondrocytes / drug effects
  • Chondrocytes / immunology
  • Collagen Type II / genetics
  • Collagen Type II / metabolism
  • Disease Models, Animal
  • Down-Regulation*
  • Humans
  • Interleukin-1beta / pharmacology
  • Interleukin-3 / administration & dosage
  • Interleukin-3 / pharmacology
  • Interleukin-3 / therapeutic use*
  • Interleukin-3 Receptor alpha Subunit / genetics
  • Interleukin-3 Receptor alpha Subunit / metabolism
  • Matrix Metalloproteinases / genetics*
  • Matrix Metalloproteinases / metabolism
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / immunology
  • Mice
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / immunology
  • Osteoarthritis / physiopathology
  • SOX9 Transcription Factor / genetics
  • SOX9 Transcription Factor / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Collagen Type II
  • IL3RA protein, human
  • Interleukin-1beta
  • Interleukin-3
  • Interleukin-3 Receptor alpha Subunit
  • SOX9 Transcription Factor
  • Sox9 protein, mouse
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinases